Illumina Provides Investment Funding To Desktop Genetics For DESKGEN Platform

(RTTNews) - Illumina Inc. (ILMN), a next-generation sequencing technology company, announced Wednesday that it has provided investment funding to Desktop Genetics Ltd, a software company revolutionizing the way biologists use CRISPR gene editing technology.

The investment will be used to fund the continued development and commercialization of the DESKGEN platform with a particular focus on integration with NGS pipelines.

The investment from Illumina follows DTG's recent fundraising from a syndicate of venture capitalists and angel investors. This combined funding is being used to continue developing DTG's proprietary DESKGEN genome editing software platform and core CRISPR algorithms.

The company said the DESKGEN platform makes CRISPR gene editing more predictable, accessible and efficient, providing scientists with the capabilities they need to scale their genomics research.

Nicholas Naclerio, SVP of Corporate and Venture Development at Illumina, said, "We have been impressed by DTG's proprietary DESKGEN platform for CRISPR-based gene editing. CRISPR is becoming increasingly important for NGS applications, and we are pleased to support DTG in executing their vision to build this market."